Skip to main content
Equibles
TYRA logo

TYRA · Tyra Biosciences, Inc.

Track TYRA — free

Use TYRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TYRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$24.94 -1.19 (-4.55%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$1.49B
Shares
59.68M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$24.94 Open$25.88 Day$24.91–25.88 52W close$11.82–39.61 Avg vol 30d550K Short int9.7M · 16.2% float · 12.7d Short vol61% Last earningsAug 4, 2026 DataSep 2021–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Dec 21, 2026 Est · unconfirmed · in 16 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −15%
below
RSI (14) 37
neutral
MACD trend Positive
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −26%
trailing
YTD return −5%
this year
Relative strength −40%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $29 › 200d $30 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.24% of float · ▲ +4.8% MoM · 12.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
172 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Poor
EPS growth −33%
Y/Y
Free cash flow $-95.3M
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −37%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
37 Neutral
MACD trend
Positive Bullish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $30 — 200d above 50d
Institutional flow Accumulating
+5% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.24% of float · ▲ +4.8% MoM · 12.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
172 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12 Now $25 · 47% Range high $40
vs 200-day avg -17% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, Cash Equivalents and Short-Term Investments $383.5M Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TYRA
Tyra Biosciences, Inc.
this stock
$1.49B -5.1% — — 16.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
172
% held
117.0%
Net QoQ
+3.4M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
192
View
Short & Settlement
Short Interest Rising
Shares short
9.7M
Days to cover
12.7d
Change
+442.5K sh
View
Short Volume
Short vol %
61%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
536
Value
$17.7K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
36.6%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-119.9M
EPS diluted
$-2.01
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
12
View
Proposed Sales
Value
$2.0M
Shares
53.2K
Filed
Mar 26, 2026
View
Exempt Offerings
Offering
$200.0M
Filed
Feb 13, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
TYRA -4.3% -21.8% -26.1% -21.8% -5.1%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -4.7% -24.8% -39.5% -24.8% -18.0%
Key facts CIK 1863127 CUSIP 90240B106 13F (30d) 155 filings 154 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)